Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease - An update

Expert Review of Clinical Immunology

Volumn 9, Issue 4, 2013, Pages 301-306

  Cesarini, Monica ^a   Fiorino, Gionata ^b  

^a POLICLINICO UMBERTO I   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

anti integrins; antiadhesion molecules; Crohn's disease; inflammatory bowel disease; leukocyte recruitment; ulcerative colitis; vedolizumab

Indexed keywords

AJM 300; ALICAFORSEN; ALPHA4 INTEGRIN; AMG 181; ANTIINFECTIVE AGENT; BETA1 INTEGRIN; BETA7 INTEGRIN; ETROLIZUMAB; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G2; INTEGRIN RECEPTOR; INTERCELLULAR ADHESION MOLECULE 1; NATALIZUMAB; PF 00547659; PLACEBO; UNCLASSIFIED DRUG; VEDOLIZUMAB;

ARTICLE; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; ENTERITIS; HUMAN; JC VIRUS; LEUKOCYTE; LEUKOCYTE MIGRATION; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REMISSION; SINGLE DRUG DOSE; ULCERATIVE COLITIS;

ANIMALS; CELL ADHESION; CELL MOVEMENT; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASES; INTEGRINS; LEUKOCYTES; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84875945634     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.13.11     Document Type: Article

References (29)

1. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 12(30), 4807-4812 (2006
2. Fiocchi C. Intestinal inflammation: A complex interplay of immune and nonimmune cell interactions. Am. J. Physiol. 273(4 Pt 1), G769-G775 (1997
3. Fiorino G, Correale C, Fries W, Repici A, Malesci A, Danese S. Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease. Expert Rev. Clin. Immunol. 6(4), 567-572 (2010
4. Shimaoka M, Springer TA. Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. 2(9), 703-716 (2003
5. Rutella S, Fiorino G, Vetrano S et al. Infliximab therapy inhibits inflammationinduced angiogenesis in the mucosa of patients with Crohn's disease. Am. J. Gastroenterol. 106(4), 762-770 (2011
6. Ghosh S, Goldin E, Gordon FH et al.; Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348(1), 24-32 (2003
7. •• First large randomized controlled trial on anti-integrin agents in inflammatory bowel disease (IBD Sandborn WJ, Colombel JF, Enns R et al.; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353(18), 1912-1925 (2005
8. Targan SR, Feagan BG, Fedorak RN et al.; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Natalizumab for the treatment of active Crohn's disease: Results of the ENCORE Trial. Gastroenterology 132(5), 1672-1683 (2007
9. Van Assche G, Van Ranst M, Sciot R et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353(4), 362-368 (2005
10. Yousry TA, Major EO, Ryschkewitsch C et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N. Engl. J. Med. 354(9), 924-933 (2006
11. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-a4b7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 330(3), 864-875 (2009
12. Parikh A, Leach T, Wyant T et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled Phase 2 dose-ranging study. Inflamm. Bowel Dis. 18(8), 1470-1479 (2012
13. Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the a4b7 integrin. N. Engl. J. Med. 352(24), 2499-2507 (2005
14. Feagan BG, Rutgeerts PJ, Sands BE et al. Induction therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter Phase 3 trial. Gastroenterol. 142(5), S160-S161 (2012
15. Takazoe M, Watanabe M, Kawaguchi T et al Oral a-4 integrin inhibitor (AJM300 in patients with active Crohn's disease - a randomized, double-blind, placebo-controlled trial. Gastroenterol. 136(5 Suppl. 1), A181 (2009
16. Rutgeerts PJ, Fedorak RN, Hommes DW et al. A randomised Phase I study of etrolizumab (rhuMAb ß7) in moderate to severe ulcerative colitis. Gut doi:10.1136/gutjnl-2011-301769 (2012) (Epub ahead of print
17. Fiorino G, Rovida S, Correale C, Malesci A, Danese S. Emerging biologics in the treatment of inflammatory bowel disease: What is around the corner? Curr. Drug Targets 11(2), 249-260 (2010
18. Bekker P, Velde A, Pronk I et al Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease. Inflamm. Bowel Dis. 13(5), 647 (2007
19. Bekker P, Petryka R, Vanasek T et al. Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial. Inflamm. Bowel Dis. 14(Suppl. 1), S11 (2008
20. Bekker P, Keshav S, Johnson D, Schall T. PROTECT-1 maintenance phase study results demonstrate efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in Crohn's disease. Inflamm. Bowel Dis. 15(12), S11 (2009
21. Hetzel DJ, Badov D, Connell W et al. CCX282-B (TRAFICET-EN (TM)), a chemokine receptor CCR9 selective antagonist, is an effective treatment for patients with moderate to severe Crohn's disease. J. Gastroenterol. Hepatol. 24, A312-A313 (2009
22. Keshav S, Johnson D, Bekker P, Schall TJ. PROTECT-1 study demonstrated efficacy of the intestine-specific chemokine receptor antagonist CCX282-B (Traficet-EN) in treatment of patients with moderate to severe Crohn's disease. Gastroenterol. 136(5 Suppl. 1), A65 (2009
23. Williamson KD, Hetzel DJ, Badov D et al. One-year results from protect-1 study of intestine-specific chemokine receptor antagonist CCX282-B in Crohn's disease. J. Gastroenterol. Hepatol. 25, A96 (2010
24. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 20(1), 1-18 (2012
25. Vermeire S, Ghosh S, Panes J et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: A randomised study. Gut 60(8), 1068-1075 (2011
26. Feagan B, Leach T, Milch C, Pankh A, Fox I. Emerging safety profile of vedolizumab: A novel, selective integrin inhibitor for the treatment of IBD. Inflamm. Bowel Dis. 15(12), S12 (2009
27. Parikh A, Leach T, Fox I, Xu J, Patella M, Feagan B. Long-term clinical experience with vedolizumab for the treatment of inflammatory bowel disease: Results of a Phase 2 open-label safety extension study. Inflamm. Bowel Dis. 17, S56 (2011
28. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: Meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol. 6(6), 644-653 (2008
29. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial. Gastroenterology 121(5), 1088-1094 (2001